Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.64% | 51.73% | 65.22% | 52.25% | 57.71% |
| Total Depreciation and Amortization | 8.29% | 0.24% | -0.10% | -0.67% | -1.27% |
| Total Amortization of Deferred Charges | 2.12% | 0.90% | 0.90% | 0.92% | 0.63% |
| Total Other Non-Cash Items | 999.72% | -29.74% | -75.11% | -38.74% | -36.44% |
| Change in Net Operating Assets | -70.54% | 16.54% | -74.79% | -234.17% | -130.86% |
| Cash from Operations | 36.01% | 51.63% | 30.43% | 16.90% | 23.29% |
| Capital Expenditure | 34.84% | 16.06% | 39.30% | -8.56% | 30.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 174.25% | 180.64% | 33.32% | -134.32% | -208.80% |
| Cash from Investing | -107.75% | 175.03% | 33.64% | -126.47% | -171.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -30.98% | -30.09% | 46.26% | 254.30% | 254.30% |
| Repurchase of Common Stock | -36.68% | -134.33% | -118.95% | -0.21% | 37.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 61.08% | -156.83% | -123.85% | 9.09% | 46.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 916.31% | 321.29% | -278.38% | -82.73% | 97.83% |